ImaginAb Inc. is pleased to announce the execution of a new non-exclusive License and Supply Agreement with Leucid Bio, a biotech company pursuing a differentiated approach to develop next generation Chimeric Antigen Receptor T-cell therapies using the Company’s proprietary Lateral CAR Platform.
